Polypharmacy (Individuals Treated With 4 or More Medications)NCT07816276
THE EFFECTS OF MULTIPLE DRUG USE ON BALANCE, FALL RISK, AND COGNITIVE STATUS
An observational study of Polypharmacy (Individuals Treated With 4 or More Medications), run by Ondokuz Mayıs University at 1 site in Turkey (Türkiye).
Trial summary
This study aims to evaluate the effects of polypharmacy on balance, fall risk, cognitive status, vestibular function, and hearing among individuals living in nursing homes. The study investigates the relationship between polypharmacy and balance, fall risk, cognitive, vestibular, and hearing-related outcomes. Read more about this study
- Who is it for?
- Ages 60 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Polypharmacy (Individuals Treated With 4 or More Medications)
- How many people
- 50 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Sep 2026to 1 Mar 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 99 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population consisted of individuals aged 60 years and older living in nursing homes in Samsun. Participants were divided into two groups according to medication use: a polypharmacy group and a control group. All participants were able to walk independently, communicate verbally, and complete the study assessments.
Who may be able to join
- Individuals aged 60 years and older
- Individuals living in nursing homes in Samsun
- Individuals in the polypharmacy group using the defined number of medications and individuals in the control group using fewer or no medications
- Ability to walk independently without an assistive device
- Ability to communicate verbally
- Voluntary participation in the study
- No complaint or diagnosis of vestibular disorder
- Ability to read and write
Who cannot join
- Individuals younger than 60 years
- Severe dementia
- Use of an assistive walking device
- Central nervous system or visual pathologies that may affect balance
- Previous diagnosis of vestibular pathology
- History of severe neurological diseases such as stroke
Show all 9Show fewer
- Inability to provide reliable responses to the assessments
- Inability to cooperate with the assessment procedures
- Inability to read and write
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Ondokuz Mayıs University
Samsun, Samsun, 55139
Ondokuz Mayıs University, +90 362 312 19 19, iletisim@omu.edu.tr
Handan TURAN DİZDAR, PhD, +9005055970627, handan.dizdar@omu.edu.tr
About this study
Official title: EVALUATION OF THE EFFECTS OF MULTIPLE MEDICATION USE ON BALANCE, FALL RISK, AND COGNITIVE STATUS IN ELDERLY INDIVIDUALS LIVING IN NURSING HOMES
This study aims to evaluate the effects of polypharmacy on balance, fall risk, cognitive status, vestibular function, and hearing among individuals living in nursing homes. The study investigates the relationship between polypharmacy and balance, fall risk, cognitive, vestibular, and hearing-related outcomes.
Read the detailed description
This study aims to investigate the effects of polypharmacy on balance, fall risk, cognitive status, vestibular function, and hearing in individuals living in nursing homes. The study will evaluate the potential relationships between polypharmacy and cognitive status, balance performance, fall risk, vestibular functions, and hearing outcomes. Participants will undergo detailed assessments (Standardized Mini-Mental State Examination, Berg Balance Scale, Tinetti Test, Timed Up and Go Test, Functional Reach Test, Cognitive Vestibular Function Scale, and pure tone audiometry); the findings will be compared with control group data and analyzed.
- Keywords
- Berg Balance Scale, Cognitive Vestibular Scale, Balance, Geriatric Individual, Mini-Mental State Examination, Polypharmacy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Study Group | Polypharmacy Group: Individuals living in nursing homes who use four or more medications. | |
| Control Group | Control Group: Individuals living in nursing homes who use fewer than four medications or no medications. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Standardized Mini-Mental State Examination
Description: Individuals' cognitive status was assessed using the Standardized Mini-Mental State Examination and compared between the polypharmacy group and the control group.
Measured: Baseline
Cognitive-Vestibular Function Scale
Individuals' cognitive-vestibular functions were assessed using the Cognitive-Vestibular Function Scale and compared between the polypharmacy group and the control group.
Measured: Baseline
Secondary outcomes (5)
6-Meter Walk Test
Description: Individuals' gait speed was assessed using the 6-Meter Walk Test and compared between the polypharmacy group and the control group.
Measured: Baseline
Functional Reach Test
Description: Individuals' dynamic balance and functional reach performance were assessed using the Functional Reach Test and compared between the polypharmacy group and the control group.
Measured: Baseline
Timed Up and Go Test
Description: Individuals' functional mobility and fall risk were assessed using the Timed Up and Go Test and compared between the polypharmacy group and the control group.
Measured: Baseline
Tinetti Balance and Gait Test
Description: Individuals' balance and gait performance were assessed using the Tinetti Balance and Gait Test and compared between the polypharmacy group and the control group.
Measured: Baseline
Berg Balance Scale
Description: Individuals' balance performance was assessed using the Berg Balance Scale and compared between the polypharmacy group and the control group.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2026
- Study start1 Sep 2026 (estimated)
- Primary completion1 Feb 2027 (estimated)
- Study completion1 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Polypharmacy (Individuals Treated With 4 or More Medications)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ondokuz Mayıs University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Handan Turan Dizdar, Ondokuz Mayıs University
- Investigators
- Handan TURAN DİZDAR, PhD, Principal investigator, Ondokuz Mayıs University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07816276
- Sponsor's protocol ID
- 2025/59
- Status last verified
- Aug 2026
- First submitted
- 7 Sep 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared with other researchers. Only aggregate study results will be reported in the publication.